866-997-4948(US-Canada Toll Free)

Diabetic Macular Edema - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 188 Pages

Diabetic Macular Edema - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema Pipeline Review, H1 2017, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 20, 5, 1, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Macular Edema - Overview 8
Diabetic Macular Edema - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Diabetic Macular Edema - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Diabetic Macular Edema - Companies Involved in Therapeutics Development 30
Aciont Inc 30
ActiveSite Pharmaceuticals Inc 30
Acucela Inc 31
Aerpio Therapeutics Inc 31
Allergan Plc 32
Ampio Pharmaceuticals Inc 32
Araim Pharmaceuticals Inc 33
Boehringer Ingelheim GmbH 33
Cell Medica Ltd 34
Chengdu Kanghong Pharmaceuticals Group Co Ltd 34
Chong Kun Dang Pharmaceutical Corp 35
Clearside BioMedical Inc 35
Coherus BioSciences Inc 36
EyeGate Pharmaceuticals Inc 36
F. Hoffmann-La Roche Ltd 37
Formycon AG 37
Genmab A/S 38
GlaxoSmithKline Plc 38
Icon Bioscience Inc 39
Kala Pharmaceuticals Inc 39
Kalvista Pharmaceuticals Ltd 40
Kowa Company Ltd 40
Lupin Ltd 41
Mabion SA 41
Oculis ehf 42
Ohr Pharmaceutical Inc 42
Oxular Ltd 43
Pfizer Inc 43
pSivida Corp 44
Regeneron Pharmaceuticals Inc 44
Santen Pharmaceutical Co Ltd 45
SciFluor Life Sciences LLC 45
Senju Pharmaceutical Co Ltd 46
Stealth BioTherapeutics Inc 46
ThromboGenics NV 47
Verseon Corp 47
Xbrane Biopharma AB 48
Diabetic Macular Edema - Drug Profiles 49
(aflibercept + nesvacumab) - Drug Profile 49
abicipar pegol - Drug Profile 51
ACU-6151 - Drug Profile 55
ACX-107 - Drug Profile 56
aflibercept biosimilar - Drug Profile 57
aflibercept biosimilar - Drug Profile 58
AKB-9778 - Drug Profile 59
ALG-1001 - Drug Profile 63
Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 67
ARP-1536 - Drug Profile 68
ASPPDC-010 - Drug Profile 69
BI-1026706 - Drug Profile 70
Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 72
brolucizumab - Drug Profile 73
bromfenac sodium - Drug Profile 75
cibinetide - Drug Profile 76
conbercept - Drug Profile 79
danazol - Drug Profile 81
darapladib - Drug Profile 85
dexamethasone acetate - Drug Profile 88
dexamethasone acetate - Drug Profile 93
dexamethasone dipropionate XR - Drug Profile 94
dexamethasone palmitate - Drug Profile 95
difluprednate - Drug Profile 96
Drug for Diabetic Macular Edema - Drug Profile 97
EBI-031 - Drug Profile 98
elamipretide - Drug Profile 99
fluocinolone acetonide SR - Drug Profile 107
HO-10 - Drug Profile 116
JDE-006 - Drug Profile 117
KPI-285 - Drug Profile 118
KVD-001 - Drug Profile 119
LKA-651 - Drug Profile 121
loteprednol etabonate - Drug Profile 122
NM-108 - Drug Profile 125
PF-655 - Drug Profile 126
ranibizumab biosimilar - Drug Profile 129
ranibizumab biosimilar - Drug Profile 130
ranibizumab biosimilar - Drug Profile 131
ranibizumab biosimilar - Drug Profile 133
ranibizumab biosimilar - Drug Profile 134
ranibizumab biosimilar - Drug Profile 135
RG-7716 - Drug Profile 136
ripasudil - Drug Profile 138
SF-0166 - Drug Profile 140
Small Molecule for Diabetic Macular Edema - Drug Profile 142
Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema - Drug Profile 143
Small Molecules to Inhibit Plasma Kallikrein for Diabetic Macular Edema - Drug Profile 144
squalamine lactate - Drug Profile 145
teprotumumab - Drug Profile 153
TG-931 - Drug Profile 155
THR-149 - Drug Profile 156
THR-317 - Drug Profile 157
triamcinolone acetonide - Drug Profile 160
triamcinolone acetonide - Drug Profile 161
VA-999272 - Drug Profile 167
Diabetic Macular Edema - Dormant Projects 168
Diabetic Macular Edema - Discontinued Products 170
Diabetic Macular Edema - Product Development Milestones 171
Featured News & Press Releases 171
Appendix 183
Methodology 183
Coverage 183
Secondary Research 183
Primary Research 183
Expert Panel Validation 183
Contact Us 183
Disclaimer 184

List of Tables
Number of Products under Development for Diabetic Macular Edema, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Diabetic Macular Edema - Pipeline by Aciont Inc, H1 2017
Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017
Diabetic Macular Edema - Pipeline by Acucela Inc, H1 2017
Diabetic Macular Edema - Pipeline by Aerpio Therapeutics Inc, H1 2017
Diabetic Macular Edema - Pipeline by Allergan Plc, H1 2017
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H1 2017
Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H1 2017
Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Diabetic Macular Edema - Pipeline by Cell Medica Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H1 2017
Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H1 2017
Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Formycon AG, H1 2017
Diabetic Macular Edema - Pipeline by Genmab A/S, H1 2017
Diabetic Macular Edema - Pipeline by GlaxoSmithKline Plc, H1 2017
Diabetic Macular Edema - Pipeline by Icon Bioscience Inc, H1 2017
Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals Inc, H1 2017
Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Kowa Company Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Lupin Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Mabion SA, H1 2017
Diabetic Macular Edema - Pipeline by Oculis ehf, H1 2017
Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc, H1 2017
Diabetic Macular Edema - Pipeline by Oxular Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Pfizer Inc, H1 2017
Diabetic Macular Edema - Pipeline by pSivida Corp, H1 2017
Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co Ltd, H1 2017
Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H1 2017
Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc, H1 2017
Diabetic Macular Edema - Pipeline by ThromboGenics NV, H1 2017
Diabetic Macular Edema - Pipeline by Verseon Corp, H1 2017
Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2017
Diabetic Macular Edema - Dormant Projects, H1 2017
Diabetic Macular Edema - Dormant Projects, H1 2017 (Contd..1), H1 2017
Diabetic Macular Edema - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Diabetic Macular Edema, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *